

## **Paradigm Investor Presentation**

**Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”)**, a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, wishes to share the presentation materials to all shareholders, that will be presented at today’s investor webinar.

The presentation is available on the Paradigm website via the following link:

<https://paradigmbiopharma.com/investors/presentations/>

Paradigm Chairman, Paul Rennie, interim CEO Dr Donna Skerrett, CSO Dr Ravi Krishnan and CFO Justin Cahill will be presenting to current and future Paradigm shareholders at 12:30pm (AEDT).

### **About Paradigm Biopharmaceuticals**

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection or genetic predisposition. Paradigm is also investigating proof-of-concept for the use of PPS in respiratory and heart failure indications.

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

#### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Simon White

Director of Investor Relations

Tel: +61 404 216 467

**Paradigm Biopharmaceuticals Ltd**

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)